Ozaki KI - Search Results

1

Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins.

Kumagai A, Shimizu K, Kurata R, Cui X, Isagawa T, Harada M, Nagai J, Yoshida Y, Ozaki KI, Takeda N, Semba H, Yonezawa T. Kumagai A, et al. Among authors: ozaki ki. Curr Pharm Biotechnol. 2019;20(1):47-55. doi: 10.2174/1389201020666190206203640. Curr Pharm Biotechnol. 2019. PMID: 30727885

2

Establishment of Novel Reporter Cells Stably Maintaining Transcription Factor-driven Human Secreted Alkaline Phosphatase Expression.

Kurata R, Kumagai A, Cui X, Harada M, Nagai J, Yoshida Y, Ozaki KI, Tanaka Y, Yonezawa T. Kurata R, et al. Among authors: ozaki ki. Curr Pharm Biotechnol. 2018;19(3):224-231. doi: 10.2174/1389201019666180418093334. Curr Pharm Biotechnol. 2018. PMID: 29667554

3

TNF-α Induces Caspase-1 Activation Independently of Simultaneously Induced NLRP3 in 3T3-L1 Cells.

Furuoka M, Ozaki K, Sadatomi D, Mamiya S, Yonezawa T, Tanimura S, Takeda K. Furuoka M, et al. J Cell Physiol. 2016 Dec;231(12):2761-7. doi: 10.1002/jcp.25385. Epub 2016 Mar 30. J Cell Physiol. 2016. PMID: 26989816

4

Targeting the extracellular signal-regulated kinase pathway in cancer therapy.

Kohno M, Tanimura S, Ozaki K. Kohno M, et al. Biol Pharm Bull. 2011;34(12):1781-4. doi: 10.1248/bpb.34.1781. Biol Pharm Bull. 2011. PMID: 22130230 Free article. Review.

5

[Targeted molecular strategies for cancer therapy based on the blockage of oncogenic pathways in human tumor cells].

Ozaki K. Ozaki K. Yakugaku Zasshi. 2007 Jun;127(6):983-91. doi: 10.1248/yakushi.127.983. Yakugaku Zasshi. 2007. PMID: 17541249 Free article. Review. Japanese.

6

Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.

Sakamoto T, Ozaki K, Fujio K, Kajikawa SH, Uesato S, Watanabe K, Tanimura S, Koji T, Kohno M. Sakamoto T, et al. Biochem Biophys Res Commun. 2013 Apr 19;433(4):456-62. doi: 10.1016/j.bbrc.2013.03.009. Epub 2013 Mar 15. Biochem Biophys Res Commun. 2013. PMID: 23501104

7

Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.

Fujiwara Y, Kawada K, Takano D, Tanimura S, Ozaki K, Kohno M. Fujiwara Y, et al. Biochem Biophys Res Commun. 2006 Feb 10;340(2):560-6. doi: 10.1016/j.bbrc.2005.12.039. Epub 2005 Dec 19. Biochem Biophys Res Commun. 2006. PMID: 16378598

8

Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin.

Hattori Y, Shibuya K, Kojima K, Miatmoko A, Kawano K, Ozaki K, Yonemochi E. Hattori Y, et al. Int J Oncol. 2015 Jul;47(1):211-9. doi: 10.3892/ijo.2015.2991. Epub 2015 May 7. Int J Oncol. 2015. PMID: 25955490

9

Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated.

Fujiwara Y, Hosokawa Y, Watanabe K, Tanimura S, Ozaki K, Kohno M. Fujiwara Y, et al. Mol Cancer Ther. 2007 Mar;6(3):1133-42. doi: 10.1158/1535-7163.MCT-06-0639. Mol Cancer Ther. 2007. PMID: 17363506

10

Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.

Ozaki K, Kosugi M, Baba N, Fujio K, Sakamoto T, Kimura S, Tanimura S, Kohno M. Ozaki K, et al. Biochem Biophys Res Commun. 2010 Jan 22;391(4):1610-5. doi: 10.1016/j.bbrc.2009.12.086. Epub 2009 Dec 22. Biochem Biophys Res Commun. 2010. PMID: 20026060 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters